The primary objective of the study is to evaluate the effect of two doses of UC1010 on premenstrual symptoms in women with PMDD in comparison to placebo. The effect of UC1010 given repeatedly to women with PMDD as subcutaneous injections during the luteal phase of three consecutive menstrual cycles will be compared with a corresponding placebo administration. Effect will be assessed by comparison of symptoms recorded daily by the patients using a validated rating scale also used for the diagnosis of PMDD.